Systems Pharmacology and Mechanistic Modeling to Accelerate and De-risk Drug R&D

Model-Aided Drug Invention

Applied BioMath specializes in mechanistic, mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies.  We bring our expansive mathematical expertise, deep understanding of biology related to many therapeutic and disease areas, and industry experience to your specific project.

Learn more >

"Using Applied BioMath’s approach, we plan to identify critical parameters which will help prioritize experiments, provide early indicators of what optimal drug properties would be for each molecule, and ultimately help us determine which molecules are best to pursue. Knowing early on what the optimal affinities, avidities, and half-lives, rather than after phase I or phase II, can potentially save millions of dollars up front, and potentially 100’s of millions later."
Tom O'Shea, PhD - Sanofi

How We Are Unique

Our Modeling Approach

A rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms.

Learn More

Industry Experience

Over 100 years of cumulative industry experience spanning the entire therapeutic workflow from early research to clinical pharmacology and regulatory filings. 

Learn More

Proprietary Technology

Our modeling process, proprietary technology, and high-performance computing allow us to conduct large-scale simulations quickly and accurately, without having to take unnecessary shortcuts on the biology or the mathematics.

Learn More

Our Foundations

Mechanistic Modeling

Iterative Collaborations

Interdisciplinary Teams

case study

The goal of this collaboration was to develop a QSP model to support translation from preclinical to clinical studies, and first-in-human (FIH) studies and to use this QSP model to provide a deeper understanding of the mechanisms of hUGT1A1-modRNA and to guide design of the first-in-human clinical studies.